Expanding the Frontiers of Breast Cancer Management
Practical Approaches to Empower Patient-Centered Care
In recent years, breast cancer treatment has evolved significantly with a focus on personalized medicine and patient-centered care. Therapeutic advances, such as a focus on targeted treatments—including antibody drug conjugates and expanded immunotherapeutic approaches—have led to unprecedented survival outcomes, even in challenging subtypes such as triple-negative breast cancer. Now, more than ever, as patients are living longer with these treatment innovations, the focus of care must be multifactorial and multidisciplinary; patient-centric care is key to improving outcomes and sustained quality of life.
LEARNING MODULES
0.5 CME CREDIT • MARCH 29, 2024
HER2-Positive Breast Cancer: Expert Insights on Evolving Data, Sequencing/Patient Selection, and Adverse Event Management With Antibody-Drug Conjugates
1 03-28-2025Erika P. Hamilton, MD
Sarah Cannon Research
Institute
Nashville, Tennessee, USA
Komal Jhaveri, MD, FACP
Memorial Sloan Kettering
Cancer Center
Weill Cornell Medical College
New York, New York, USA
Sarah Donahue, MPH, ANP, AOCNP
University of
California, San Francisco
San Francisco, California, USA
In this module
- Overview of Approved and Emerging ADCs for the Treatment of HER2+ Advanced Breast Cancer in the Second Line and Beyond
- Efficacy of Approved and Emerging ADCs for the Treatment of HER2+ Advanced Breast Cancer in the Second Line and Beyond
- Efficacy of Approved and Emerging ADCs in Patients With HER2+ Advanced Breast Cancer in the Second Line and Beyond: Considerations for Brain Metastases
- Safety of Approved and Emerging ADCs for the Treatment of HER2+ Advanced Breast Cancer in the Second Line and Beyond
- Strategies to Manage Common Side Effects Associated With Approved ADCs for the Treatment of HER2+ Advanced Breast Cancer in the Second Line and Beyond
0.5 CME CREDIT • MARCH 22, 2024
The Patient-Clinician Alliance to Enhance Care for Patients With Metastatic Breast Cancer on Antibody-Drug Conjugates
2 03-21-2025Laura Spring, MD
Harvard Medical
School
Boston, Massachusetts, USA
Janice Cowden
Florida, USA
In this module
- Linking Concept to Practice: The Rationale for Antibody Drug Conjugates in Metastatic Breast Cancer
- Coupling Proactive Adverse Event Management With Enhanced Outcomes: Focus on the Safety Profile of TROP-2 Directed ADCs
- Aligning Proactive Care With Improved Outcomes: Targeting the Adverse Event Profile of HER2-Directed ADCs
- Shared Decision-Making in Patients Eligible for ADCs: Enhancing a Cornerstone of Care
- Charting a Long-Term Plan for Patients With Metastatic Breast Cancer: A Conversation About Survivorship
0.5 CME CREDIT • MARCH 21, 2024
Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer
3 03-20-2025Aditya Bardia, MD
University of California, Los
Angeles
Los Angeles, California, USA
In this module
- Being Sensitive to Real-World Care: Guiding Principles in Managing ER-Positive, HER2-Negative Advanced Breast Cancer After Progression
- Being Focused on Evidence-Based Care: Reviewing the Clinical Impact of CDK4/6 Inhibitor Rechallenge
- Targeting Alternative Pathways of Disease Progression After Recurrence on CDK4/6I Plus Endocrine Therapy
- Pinpointing the Impact of Evidence-Based Treatment: Evaluating the Clinical Effect of Oral SERDs After Recurrence on CDK4/6I Plus Endocrine Therapy
- Being Diligent to Enhance Patient Safety: Evaluating the Clinical Impact of Current Therapeutic Options
- Strategies to Stand the Test of Time: Integrating Biomarker Testing Into Clinical Practice
- Being Practical for Real-World Results: A Personalized Approach to Management of ER-Positive, HER2-Negative Advanced Breast Cancer
0.5 CME CREDIT • FEBRUARY 29, 2024
Targeting a Suspected Culprit in Resistance and Progression of HR-Positive, HER2-Negative Advanced Breast Cancer: The Role of the PI3K/AKT/mTOR Pathway
4 02-28-2025Komal Jhaveri, MD, FACP
Memorial Sloan Kettering
Cancer Center
Weill Cornell Medical College
New York, New York, USA
In this module
- Detecting the Need for Second-Line Therapies to Overcome Resistance to Endocrine-Based Regimens
- Targeting the PI3K/AKT/mTOR Pathway to Overcome Treatment Resistance and Disease Progression
- Gathering Evidence on the Efficacy of Agents That Target the PI3K/AKT/mTOR Pathway
- Clueing Into the Safety of Agents That Target the PI3K/AKT/mTOR Pathway
- Deducing the Clinical Implications of the Evidence on Agents That Target the PI3K/AKT/mTOR Pathway
0.5 CME CREDIT • DECEMBER 4, 2023
Getting Real With Patients During Clinical Decision-Making: The Value of Sharing Real-World Evidence About CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer
5 12-03-2024Adam Brufsky, MD, PhD
University of
Pittsburgh
Pittsburgh, Pennsylvania, USA
In this module
- Improving Patient Awareness of the Utility of RWE on the Frontline Use of CDK4/6 Inhibitors in HR+/HER2- mBC
- Considering Real-World Efficacy Data for CDK4/6 Inhibitors in HR+/HER2- mBC
- Evaluating Real-World Safety Data for CDK4/6 Inhibitors in HR+/HER2- mBC
- Factoring in Real-World Data for CDK4/6 Inhibitor Regimens in HR+/HER2- mBC
- Discussing Patient Preferences and Values, Informed by RWE
0.5 CME CREDIT • SEPTEMBER 14, 2023
Using a Roadmap to Guide the Journey: Integrating Germline BRCA Testing Into the Care of Patients With HER2-Negative Early-Stage Breast Cancer
6 09-13-2024Charles E. Geyer, MD, FACP
UPMC Hillman Cancer
Center
Pittsburgh, Pennsylvania, USA
Joyce O'Shaughnessy, MD
SCRI/ Baylor University
Medical Center
Dallas, Texas, USA
In this module
- Guideline Recommendations on BRCA Testing in Breast Cancer
- Strategies to Integrate BRCA Testing in Your Clinic
- Identifying Barriers to BRCA Testing
- Clinical Evidence on PARP Inhibitors for the Treatment of BRCA-Positive Early Breast Cancer: A Focus on Efficacy
- Clinical Evidence on PARP inhibitors for the Treatment of BRCA-Positive Early Breast Cancer: A Focus on Safety Considerations
0.5 CME CREDIT • AUGUST 11, 2023
Striving Toward Health Equity in Metastatic Breast Cancer: Patient-Centered Conversations to Address Social Determinants of Health
7 08-10-2024Erica Stringer-Reasor, MD
University of Alabama
at Birmingham
Birmingham, Alabama, USA
In this module
- Raising Awareness of Racial Disparities in Patient Outcomes for Metastatic Breast Cancer
- Factors Contributing to Poorer Outcomes for Black Patients With Breast Cancer
- Comparing Racial Differences in Utilization of Breast Cancer Care
- Common Patient Concerns and Opportunities for Improvement
- Practical Strategies to Mitigate Racial Disparities in Breast Cancer Care
0.5 CME CREDIT • JUNE 26, 2023
Integrating Advances in HR+ HER2- Early Breast Cancer: A Focus on Targeted Adjuvant Regimens
8 06-25-2024Sara A. Hurvitz, MD, FACP
David Geffen School of
Medicine at UCLA
Los Angeles, California, USA
Miguel Martín, MD, PhD
Universidad Complutense de
Madrid
Hospital General Universitario Gregorio Marañon
Madrid, Spain
In this module
- Assessing Risk of Recurrence in HR+ HER2- Early Breast Cancer
- Recommendations on the Use of Oral Targeted Adjuvant Therapies in Patients With HR+ HER2- Early Breast Cancer
- Impact of Oral Targeted Adjuvant Therapies in Patients With HR+ HER2- Early Breast Cancer
- Safety Profiles of Oral Targeted Adjuvant Therapies in Patients With HR+ HER2- Early Breast Cancer
- Optimizing Adherence and Persistence With Oral Targeted Adjuvant Therapies in HR+ HER2- Early Breast Cancer
0.5 CME CREDIT • JUNE 9, 2023
Putting Patients First: Optimizing Outcomes via Collaborative Care in Pretreated Advanced Triple Negative Breast Cancer Treatment
9 06-08-2024Javier Cortés, MD
International Breast Cancer
Center (IBCC)
Barcelona, Spain
Sarah Donahue, MPH, ANP, AOCNP
University of
California, San Francisco
San Francisco, California, USA
In this module
- Keeping an Eye on Patient Needs: Reviewing the Benefit and Risk Profiles of Novel Targeted Therapies for Advanced TNBC
- A Spotlight on Best Practices to Manage Key Adverse Events Associated With Antibody-Drug Conjugates for Advanced TNBC
- Targeting Optimal Outcomes With PARP Inhibitors in Advanced TNBC: Managing Key Adverse Events
- Converging on Optimal Adverse Event Management in Advanced TNBC: The Need for Multidisciplinary Approaches
- Honing In on Collaborative Approaches to Improve Holistic Care of Patients With Advanced TNBC: Strategies to Improve Survivorship
0.5 CME CREDIT • JANUARY 27, 2023
Closing the Racial Disparity Gap in the Management of Breast Cancer
10 01-26-2024Erica Stringer-Reasor, MD
University of Alabama
at Birmingham
Birmingham, Alabama, USA
In this module
- A Clinician’s Guide to Addressing Key Racial Disparities That Hinder the Treatment of Breast Cancer
- Advancing Care for Black and Hispanic Women With Breast Cancer: Evaluating the Evolution of Care
- Effective Communication, Enhanced Patient Engagement: Strategies to Improve Patient-Centered Care in Breast Cancer
- Comprehensive Care to Improve Overall Patient Management: Elevating Outcomes in Underrepresented Patients With Breast Cancer
- Proactive Approaches to Elevate Quality of Life in Underrepresented Patients With Breast Cancer
0.5 CME CREDIT • JANUARY 23, 2023
Real Talk About CDK4/6 Inhibitors in the Treatment of HR+/HER2- Advanced Breast Cancer: Using Real-World Evidence to Impact Patient Outcomes
11 01-22-2024Richard Finn, MD
Geffen School of Medicine at
UCLA
Los Angeles, California, USA
In this module
- Why Real World Evidence? Treatment Needs in HR+/HER2- Advanced Breast Cancer
- Real World Efficacy: What the Evidence Says About CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer
- Real World Safety Expectations for CDK4/6 Inhibitors: Clinical Implications
- Keeping It Real: How to Translate Real World Evidence to Treatment of Patients With HR+/HER2- Advanced Breast Cancer
- Real Talk About CDK4/6 Inhibitors: Real World Evidence in Shared Decision-Making
0.5 CME CREDIT • NOVEMBER 2, 2022
Reducing Endocrine Resistance in Early Breast Cancer: Will Oral Selective Estrogen Receptor Degraders Provide New Hope?
12 11-01-2023Aditya Bardia, MD, MPH
Harvard Medical
School
Massachusetts Brigham Hospital
Boston, Massachusetts, USA
In this module
- Recognizing the Resistance Development Against Endocrine Therapy in Early Breast Cancer: A Focus on Patient Outcomes
- Understanding the Reasons for Resistance Development Against Endocrine Therapy in Early Breast Cancer
- Overcoming Resistance: The Clinical Rationale for Selective Estrogen Receptor Degraders in Early Breast Cancer
- Exploring the Paths With Least Resistance: Developing Oral SERDs for Adjuvant Use in Early Breast Cancer
- Maximizing Safety With Oral Selective Estrogen Receptor Degraders for Patients With ER-Positive Early Breast Cancer
0.5 CME CREDIT • OCTOBER 19, 2022
BRCA Testing in Patients With Early-Stage Breast Cancer: A Focus on the Patient Conversation
13 10-18-2023Javier Cortés, MD, PhD
International Cancer
Experts
Madrid, Spain
Tamara Bumpus, FNP-C
Toledo, Ohio, USA
In this module
- Discussing Genomic Testing With the Patient: Principles in Early-Stage Breast Cancer
- Considerations for BRCA Mutational Testing in Early-Stage Breast Cancer
- Practical Strategies to Support BRCA Mutational Testing in Patients With Early-Stage Breast Cancer
- Discussing Results With Patients: Expert Perspectives
- Tying Testing to Treatment: Aligning Patients With Novel Targeted Treatment Regimens in Early-Stage Breast Cancer
0.5 CME CREDIT • OCTOBER 17, 2022
Building Connections Between the Clinical Evidence and Practical Care: A Patient-Centered Approach to Recurrent TNBC
14 10-16-2023Aditya Bardia, MD, MPH
Harvard Medical
School
Massachusetts Brigham Hospital
Boston, Massachusetts, USA
Véronique Diéras, MD
Centre Eugène Marquis
Unicancer
Rennes, France
In this module
- The Underlying Foundation of Care for Advanced TNBC: Clinical Strategies to Enhance Patient Management
- Building on the Foundation of Care for Advanced TNBC: Evaluating the Novel Strategies
- Safety Is Key: Evaluating the Adverse Event Profiles for Novel Treatments in TNBC Care
- Quality of Life Is Key: Treatment Optimization Through Managing Adverse Effects of Novel Treatments
- Building Connections Between the Clinical Data and Practical Care: An Evidence-Based Approach to Recurrent TNBC
0.5 CME CREDIT • SEPTEMBER 30, 2022
Stay in the Know About HER2-Low: Improving Breast Cancer Outcomes With Emerging Antibody Drug Conjugates
15 09-29-2023Hope S. Rugo, MD, FASCO
University of California
San Francisco Medical Center
UCSF Helen Diller Family Comprehensive Cancer
Center
San Francisco, California, USA
In this module
- Improving Outcomes by Expanding Therapeutic Options in HER2-Low Breast Cancer
- Identifying HER2-Low Status: Don’t Be Slow to Test
- Evaluating the Data for Antibody Drug Conjugates in Previously Treated HER2-Low Advanced Breast Cancer: Can Survival Rates Grow?
- Proactive Measures to Optimize Safety With Antibody Drug Conjugates: Stay in the Know
- Advancing the Future Care of Previously Treated Patients With HER2-Low Advanced Breast Cancer: Incorporating Antibody Drug Conjugates Into the Treatment Flow
0.5 CME CREDIT • JUNE 15, 2022
Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice
16 06-14-2023Hope S. Rugo, MD, FASCO
University of California
San Francisco Medical Center
UCSF Helen Diller Family Comprehensive Cancer
Center
San Francisco, California, USA
Javier Cortés, MD, PhD
International Breast
Cancer Center, IBCC
Barcelona, Spain
In this module
- Predicting Risk of Recurrence in HR-Positive, HER2-Negative Early Breast Cancer: A Focus on Clinicopathological Factors
- Tools to Guide Risk Assessment and Adjuvant Treatment Decisions in HR-Positive, HER2-Negative Early Breast Cancer
- Evaluating Guideline-Recommended Treatment Options in the Adjuvant Setting for HR-Positive, HER2-Negative Early Breast Cancer
- Impact of CDK4/6 Inhibitors as Adjuvant Therapy in HR-Positive, HER2-Negative Early Breast Cancer: A Focus on Recent Evidence
- Safety of CDK4/6 Inhibitors as Adjuvant Therapy in HR-Positive, HER2-Negative Early Breast Cancer
0.5 CME CREDIT • MAY 5, 2022
Looking to the Future of ER-Positive Breast Cancer Treatment: Deciphering the Data and Refining the Role of Oral SERDs
17 05-04-2023Komal Jhaveri, MD
Weill Cornell Medical
College
Memorial Sloan Kettering Cancer Center
New York, New York, USA
